KR102962366B1 - 화합물, 조성물 및 방법 - Google Patents
화합물, 조성물 및 방법Info
- Publication number
- KR102962366B1 KR102962366B1 KR1020217036412A KR20217036412A KR102962366B1 KR 102962366 B1 KR102962366 B1 KR 102962366B1 KR 1020217036412 A KR1020217036412 A KR 1020217036412A KR 20217036412 A KR20217036412 A KR 20217036412A KR 102962366 B1 KR102962366 B1 KR 102962366B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- delete delete
- disease
- alkyl
- certain embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832775P | 2019-04-11 | 2019-04-11 | |
| US62/832,775 | 2019-04-11 | ||
| PCT/US2020/027742 WO2020210684A1 (en) | 2019-04-11 | 2020-04-10 | Compounds, compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210151887A KR20210151887A (ko) | 2021-12-14 |
| KR102962366B1 true KR102962366B1 (ko) | 2026-05-11 |
Family
ID=72752101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217036412A Active KR102962366B1 (ko) | 2019-04-11 | 2020-04-10 | 화합물, 조성물 및 방법 |
Country Status (19)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3086182A1 (en) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
| AU2021371697B2 (en) * | 2020-10-29 | 2024-10-24 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
| CN116120291B (zh) * | 2023-04-11 | 2023-06-30 | 英矽智能科技(上海)有限公司 | 吲唑类化合物及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180208582A1 (en) | 2016-06-16 | 2018-07-26 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101566091B1 (ko) | 2010-11-10 | 2015-11-04 | 에프. 호프만-라 로슈 아게 | Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체 |
| WO2018217946A1 (en) * | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3086182A1 (en) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
-
2020
- 2020-04-08 AR ARP200101008A patent/AR118641A1/es unknown
- 2020-04-10 SG SG11202111058XA patent/SG11202111058XA/en unknown
- 2020-04-10 US US17/602,480 patent/US12358896B2/en active Active
- 2020-04-10 MX MX2021012392A patent/MX2021012392A/es unknown
- 2020-04-10 WO PCT/US2020/027742 patent/WO2020210684A1/en not_active Ceased
- 2020-04-10 MA MA055624A patent/MA55624A/fr unknown
- 2020-04-10 CN CN202080041217.0A patent/CN113939294A/zh active Pending
- 2020-04-10 DK DK20787582.4T patent/DK3953348T3/da active
- 2020-04-10 JP JP2021559818A patent/JP7623294B2/ja active Active
- 2020-04-10 KR KR1020217036412A patent/KR102962366B1/ko active Active
- 2020-04-10 AU AU2020272045A patent/AU2020272045B2/en active Active
- 2020-04-10 ES ES20787582T patent/ES3018383T3/es active Active
- 2020-04-10 IL IL287120A patent/IL287120B2/en unknown
- 2020-04-10 TW TW109112173A patent/TWI851710B/zh active
- 2020-04-10 BR BR112021020027A patent/BR112021020027A2/pt unknown
- 2020-04-10 EA EA202192530A patent/EA202192530A1/ru unknown
- 2020-04-10 EP EP20787582.4A patent/EP3953348B1/en active Active
- 2020-04-10 CA CA3136447A patent/CA3136447A1/en active Pending
-
2021
- 2021-10-05 ZA ZA2021/07499A patent/ZA202107499B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180208582A1 (en) | 2016-06-16 | 2018-07-26 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
Also Published As
| Publication number | Publication date |
|---|---|
| ES3018383T3 (es) | 2025-05-16 |
| EP3953348B1 (en) | 2024-12-18 |
| CN113939294A (zh) | 2022-01-14 |
| AU2020272045A1 (en) | 2021-10-28 |
| IL287120B1 (en) | 2025-02-01 |
| BR112021020027A2 (pt) | 2021-12-07 |
| TWI851710B (zh) | 2024-08-11 |
| JP7623294B2 (ja) | 2025-01-28 |
| DK3953348T3 (da) | 2025-03-17 |
| WO2020210684A1 (en) | 2020-10-15 |
| JP2022526015A (ja) | 2022-05-20 |
| AR118641A1 (es) | 2021-10-20 |
| TW202104213A (zh) | 2021-02-01 |
| AU2020272045B2 (en) | 2026-01-15 |
| EP3953348A1 (en) | 2022-02-16 |
| MX2021012392A (es) | 2021-11-12 |
| CA3136447A1 (en) | 2020-10-15 |
| EA202192530A1 (ru) | 2022-03-15 |
| IL287120B2 (en) | 2025-06-01 |
| US20220220094A1 (en) | 2022-07-14 |
| EP3953348A4 (en) | 2023-01-18 |
| SG11202111058XA (en) | 2021-11-29 |
| ZA202107499B (en) | 2022-06-29 |
| IL287120A (en) | 2021-12-01 |
| KR20210151887A (ko) | 2021-12-14 |
| US12358896B2 (en) | 2025-07-15 |
| MA55624A (fr) | 2022-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI786049B (zh) | 化合物、組合物及方法 | |
| US20220153728A1 (en) | Compounds, compositions and methods | |
| JP2021505598A (ja) | 心不全およびそれに関連する障害の治療または予防に有用なβ−3アドレナリン受容体のモジュレーター | |
| JP7623294B2 (ja) | 化合物、組成物および方法 | |
| EA050027B1 (ru) | Соединения, композиции и способы | |
| HK40069073A (en) | Compounds, compositions and methods | |
| HK40069073B (en) | Compounds, compositions and methods | |
| RU2809596C2 (ru) | Соединение на основе пирроламидопиридона, способ его получения и его применение | |
| HK40074923A (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| HK40074923B (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| RU2806751C2 (ru) | Соединения на основе пиразолопиридинона | |
| EA052777B1 (ru) | Пиримидин-2-иламино-1н-пиразолы в качестве ингибиторов lrrk2 для применения при лечении нейродегенеративных заболеваний | |
| EA052117B1 (ru) | Пиримидин-2-иламино-1н-пиразолы в качестве ингибиторов lrrk2 для применения при лечении нейродегенеративных заболеваний | |
| HK40007576B (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| OA19864A (en) | Compounds, compositions, and methods. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |